Senior–Løken syndrome
Senior–Løken syndrome is a rare genetic disorder characterized by a combination of nephronophthisis (a type of kidney disease) and retinitis pigmentosa (a type of eye disease). This syndrome is part of a group of disorders known as ciliopathies, which are caused by defects in the function of cilia, the hair-like structures on the surface of cells.
Presentation[edit | edit source]
Individuals with Senior–Løken syndrome typically present with symptoms of nephronophthisis during childhood, which may include excessive thirst, frequent urination, and chronic kidney disease. The kidney disease often progresses to end-stage renal disease (ESRD) by adolescence or early adulthood.
The retinitis pigmentosa component of the syndrome leads to progressive vision loss, starting with difficulty seeing in low light conditions (night blindness) and loss of peripheral vision. Over time, this can progress to complete blindness.
Genetics[edit | edit source]
Senior–Løken syndrome is inherited in an autosomal recessive manner. This means that an individual must inherit two copies of the defective gene, one from each parent, to develop the syndrome. Several genes have been associated with Senior–Løken syndrome, including NPHP1, NPHP3, and IQCB1.
Diagnosis[edit | edit source]
Diagnosis of Senior–Løken syndrome is based on clinical findings and genetic testing. Ultrasound and other imaging techniques can be used to assess kidney function, while electroretinography and other eye exams can evaluate the extent of retinal degeneration.
Management[edit | edit source]
There is currently no cure for Senior–Løken syndrome. Management focuses on treating the symptoms and complications of the disease. This may include dialysis or kidney transplantation for kidney failure and supportive therapies for vision loss.
Prognosis[edit | edit source]
The prognosis for individuals with Senior–Løken syndrome varies depending on the severity of the kidney and eye involvement. Early diagnosis and management can improve quality of life and outcomes.
Related Pages[edit | edit source]
Categories[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD